Latest news with #CiplaLtd
Business Standard
2 days ago
- Business
- Business Standard
Cipla Ltd spurts 0.42%, up for fifth straight session
Cipla Ltd is quoting at Rs 1517.2, up 0.42% on the day as on 12:44 IST on the NSE. The stock is down 1.54% in last one year as compared to a 8.05% jump in NIFTY and a 11.69% jump in the Nifty Pharma. Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1517.2, up 0.42% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.38% on the day, quoting at 25199.55. The Sensex is at 82711.36, up 0.39%. Cipla Ltd has gained around 0.37% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has gained around 4.47% in last one month and is currently quoting at 21948, up 0.45% on the day. The volume in the stock stood at 6.69 lakh shares today, compared to the daily average of 19.71 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1524.2, up 0.71% on the day. Cipla Ltd is down 1.54% in last one year as compared to a 8.05% jump in NIFTY and a 11.69% jump in the Nifty Pharma index. The PE of the stock is 24.77 based on TTM earnings ending March 25.
Time of India
13-05-2025
- Business
- Time of India
Cipla Q4 profit jump 30% to Rs 1,222 crore; Board approves Rs 16 per share dividend
Pharmaceutical major Cipla Ltd on Tuesday reported a 30% year-on-year (YoY) rise in its consolidated net profit, which stood at Rs 1,222 crore for the fourth quarter ended March 31, 2025. The strong performance was driven by higher sales in key markets including India, the United States, and Africa. The Mumbai-based company had reported a net profit of Rs 939 crore in the corresponding quarter of the previous fiscal. Total revenue from operations rose to Rs 6,730 crore in the March quarter, up from Rs 6,163 crore a year earlier, according to the company's regulatory filing, as reported by PTI. In the domestic market, revenue increased 8% to Rs 2,622 crore, compared to Rs 2,417 crore in Q4FY24. Revenue from North America rose 2% year-on-year to Rs 1,919 crore, up from Rs 1,875 crore, while revenue from Africa posted a robust 20% growth, reaching Rs 1,019 crore during the quarter. For the full fiscal year FY25, Cipla reported a consolidated net profit of Rs 5,272 crore, marking a 28% increase over Rs 4,122 crore in FY24. Revenue from operations also grew, reaching Rs 27,548 crore as against Rs 25,774 crore in the previous financial year. "Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front," said Cipla Managing Director and Global CEO Umang Vohra. The company's Board of Directors has approved a total dividend of Rs 16 per share for FY25. This includes a final dividend of Rs 13 per share and a special dividend of Rs 3 per share, the latter announced to mark Cipla's 90th anniversary. The dividend is based on shares with a face value of Rs 2 each. Shares of Cipla ended Tuesday's trading session 0.49% higher at Rs 1,519.45 apiece on the BSE.
Business Upturn
13-05-2025
- Business
- Business Upturn
Cipla Q4 Results: Board declares Rs 16 per share dividend, includes Rs 3 special payout
By Aditya Bhagchandani Published on May 13, 2025, 13:49 IST Cipla Ltd has reported a consolidated net profit of ₹1,221.84 crore for the fourth quarter ended March 31, 2024, marking a strong 30% year-on-year increase from ₹939 crore in Q4 FY23. The company's revenue from operations for the quarter stood at ₹6,729.69 crore, up from ₹6,163.24 crore in the same period last year. Total income for the quarter came in at ₹7,019.15 crore, with EBITDA rising to ₹1,504.30 crore versus ₹1,259.26 crore in the year-ago quarter. For the full year ended March 31, 2025, Cipla reported a net profit of ₹5,272.52 crore, compared to ₹4,121.55 crore in FY23. Annual revenue rose to ₹27,547.62 crore from ₹25,774.09 crore. Final dividend announced The Board of Directors also recommended a final dividend of ₹13 per equity share and a special dividend of ₹3 per equity share on the occasion of Cipla completing 90 years, bringing the total dividend to ₹16 per equity share (face value ₹2 each). The dividend, subject to shareholder approval, will be paid within 30 days from the date of the Annual General Meeting. The record date for dividend eligibility is June 27, 2025. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Standard
06-05-2025
- Business
- Business Standard
Aurobindo Pharma Ltd Slips 3.92%, BSE Healthcare index Shed 1.06%
Aurobindo Pharma Ltd has added 8.07% over last one month compared to 3.45% gain in BSE Healthcare index and 7.28% rise in the SENSEX Aurobindo Pharma Ltd fell 3.92% today to trade at Rs 1194. The BSE Healthcare index is down 1.06% to quote at 41928.48. The index is up 3.45 % over last one month. Among the other constituents of the index, Lupin Ltd decreased 3.13% and Cipla Ltd lost 2.64% on the day. The BSE Healthcare index went up 17.28 % over last one year compared to the 9.41% surge in benchmark SENSEX. Aurobindo Pharma Ltd has added 8.07% over last one month compared to 3.45% gain in BSE Healthcare index and 7.28% rise in the SENSEX. On the BSE, 5911 shares were traded in the counter so far compared with average daily volumes of 53449 shares in the past one month. The stock hit a record high of Rs 1592.55 on 13 Sep 2024. The stock hit a 52-week low of Rs 994.35 on 07 Apr 2025.
